乐普生物(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02157 乐普生物

已收盘 10-06 16:08:03

4.015

+0.105

+2.69%

最高4.040	最低3.960	成交量28.30万
今开3.985	昨收3.910	日振幅2.05%
总市值72.43亿	流通市值72.43亿	总股本18.04亿
成交额113.33万	换手率0.02%	流通股本18.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02157","market":"HK","secType":"STK","nameCN":"乐普生物","latestPrice":4.015,"timestamp":1791274083003,"preClose":3.91,"halted":0,"volume":283000,"delay":0,"changeRate":0.026854219948848984,"floatShares":1804000000,"shares":1804000000,"eps":0.148918,"marketStatus":"已收盘","change":0.105,"latestTime":"10-06 16:08:03","open":3.985,"high":4.04,"low":3.96,"amount":1133325,"amplitude":0.02046,"askPrice":4.015,"askSize":3000,"bidPrice":4,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":0.15825,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791336600000},"marketStatusCode":5,"adr":0,"listingDate":1645545600000,"exchange":"SEHK","adjPreClose":3.91,"openAndCloseTimeList":[[1791250200000,1791259200000],[1791262800000,1791273600000]],"volumeRatio":0.033091,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02157","defaultTab":"news","newsList":[{"id":"1158954419","title":"乐普生物9月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1158954419","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158954419?lang=zh_cn&edition=full","pubTime":"2026-10-06 17:32","pubTimestamp":1791279124,"startTime":"0","endTime":"0","summary":"乐普生物科技股份有限公司2026年10月6日发布的截至2026年9月30日的证券变动月报表显示，其9月期间已发行股份及注册股本未发生变动。公司截至报告期末的法定/注册股本总额为人民币1,804,439,838元，面值为每股人民币1元。公司已发行股份合计为1,804,439,838股，与上月底持平，且无库存股份。月报亦显示，公司当月无新增股份期权、股权激励计划变动或其他形式的发行安排。截至报告期末，乐普生物总股本保持稳定。公告由联席公司秘书李昀轶女士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671222418","title":"创新药概念普涨 金斯瑞生物科技（01548）涨超10% 机构看好创新药及其产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222418","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671222418?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:35","pubTimestamp":1790735739,"startTime":"0","endTime":"0","summary":"金吾财讯  | 创新药概念普涨，截至发稿，金斯瑞生物科技 涨10.10%，石药集团涨6.07%，云顶新耀涨5.79%，恒瑞医药涨5.18%，药明合联涨4.48%，晶泰控股涨4.06%，乐普生物涨3.52%，药明生物涨3.46%。消息面上，开源证券表示，整体上，持续看好创新药及其产业链及AI、脑机接口、生物制造等国家战略新兴产业。后续可重点跟踪ESMO临床数据、三季度订单及业绩验证和政策细则落地，积极把握优质创新药、CXO及生命科学上游调整后的配置机会。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992823","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","IBBQ","IE00B0JY6N72.USD","01276","LU0307460666.USD","BK1610","BK1521","LU0516422366.SGD","LU1188198961.HKD","LU1226288170.HKD","01548","01093","IE00BZ08YR35.GBP","BK1574","02269","LNGR","LU1813983027.USD","BK1515","KURE","BK1589","IE00BZ08YT58.USD","02228","LU0029874905.USD","BK1141","BK1161","SG9999004220.SGD","LU0072913022.USD","HK0000306701.USD","LU0540923850.HKD","LU0140636845.USD","01952","LU1688375341.USD","LU0880133367.SGD","LU0128522744.USD","LU1328277881.USD","LU1807302812.USD","LU0359201885.HKD","02157","LU1880383366.USD","159992","06978","LU0708995153.HKD","LU0823426480.USD","LU1242518931.SGD","MEDX","LU1242518857.USD","LU0181495838.USD","02268","LU1008478684.HKD","LU0039217434.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671293354","title":"创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671293354","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671293354?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:20","pubTimestamp":1790659249,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股逆市走强，康方生物 涨16.85%，康诺亚-B涨10.32%，乐普生物涨7.88%，荣昌生物涨5.41%，科伦博泰生物涨5.32%，博安生物涨4.74%，恒瑞医药涨4.02%，再鼎医药涨4.02%。根据Insight数据，除已经在美国获批上市的药物外，已达成出海合作的国产创新药中有27款处于临床后期。其中，依沃西单抗、匹米替尼已在美国申请上市，芦康沙妥珠单抗、伦康依隆妥单抗、SSGJ-707等重点品种处于临床III期。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992749","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348784397.USD","LU2476274720.SGD","BK1587","BK1588","09995","LU1720050803.USD","LU1794554557.SGD","LU1969619763.USD","LU2476274308.USD","IE00B543WZ88.USD","LNGR","02157","02162","LU0348766576.USD","LU0348825331.USD","LU1023057109.AUD","09926","LU0417516738.SGD","KURE","LU2488822045.USD","LU0417516571.SGD","LU2328871848.SGD","IBBQ","LU1961090484.USD","BK1583","LU0359201885.HKD","LU0348767384.USD","LU0348735423.USD","MEDX","LU0634319403.HKD","BK1191","LU2543165471.USD","BK1161","IE00B5MMRT66.SGD","159992","LU0348783233.USD","LU0417516902.SGD","06955","LU2778985437.USD","BK1574","LU0359201612.USD","06990","LU0561508036.HKD","06978","01276","09688","IE00BPRC5H50.USD","LU0348827113.USD","LU0196878994.USD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670005044","title":"港股异动 | 乐普生物(02157)涨超4% CMG901临床研究结果入选LBA并将于主席研讨会上公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2670005044","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670005044?lang=zh_cn&edition=full","pubTime":"2026-09-28 09:51","pubTimestamp":1790560302,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，乐普生物涨超4%，截至发稿，涨3.56%，报3.935港元，成交额1193.71万港元。消息面上，乐普生物发布公告，于欧洲肿瘤内科学会年会2026年周年大会：CMG901的用于二线及后线(2L+)Claudin 18.2阳性晚期 ╱ 转移性胃食管癌III期临床试验的积极研究结果，入选重磅研究摘要并将于主席研讨会上作优选论文报告；MRG007的I期临床研究的积极结果，入选LBA并将于会上作快速口头汇报。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02157","KCAI","VXUS","BK4585","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669986109","title":"乐普生物(02157)：CMG901(AZD0901)临床研究结果入选LBA并将于主席研讨会上公布 总计4项临床研究结果入选2026年ESMO大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2669986109","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669986109?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:36","pubTimestamp":1790152598,"startTime":"0","endTime":"0","summary":"2026年ESMO大会将于2026年10月23日至27日在西班牙马德里举行。CMG901为公司与康诺亚生物医药科技有限公司(康诺亚)联合开发的靶向CLDN18.2的ADC。于2023年2月，CMG901的研究、开发、注册、生产及商业化的全球权利已授予阿斯利康，其用于治疗二线及以上晚期╱转移性Claudin 18.2阳性GEC的III期临床试验详细结果将首次于ESMO大会主席研讨会上作为LBA披露。同时，MRG007的I期临床研究结果，亦将于2026年ESMO大会上以LBA快速口头汇报形式首次披露。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139685","title":"港股创新药概念走高 乐普生物涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139685","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139685?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:00","pubTimestamp":1789956000,"startTime":"0","endTime":"0","summary":"港股创新药概念走高 乐普生物涨超8%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609213879749820.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609213879749820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","IBBQ","BK4588","02157","MEDX","BK4585","VXUS","159992","KCAI","BK1161","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180705855","title":"乐普生物2026年中期营收5.22亿元，经调整净利润0.25亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180705855","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180705855?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:39","pubTimestamp":1789547954,"startTime":"0","endTime":"0","summary":"报告期内，乐普生物实现营收5.22亿元，较上年同期的4.66亿元增长12.1%。经调整净利润为0.25亿元，相比上年同期的0.29亿元下降约15.2%。经营活动方面，期内产生经营现金流净流出约1.00亿元，而上年同期经营活动现金流为净流入约0.47亿元。报告期内，商业化产品销售收入约3.71亿元，较上年同期的1.51亿元增长约146%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"乐普生物2026年中期营收5.22亿元，经调整净利润0.25亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510786","title":"港股异动 | 创新药概念股持续调整 海外利率预期反复 2026国谈收官进入结果等待期","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510786","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666510786?lang=zh_cn&edition=full","pubTime":"2026-09-11 11:08","pubTimestamp":1789096112,"startTime":"0","endTime":"0","summary":"消息面上，2026国谈现场谈判和价格协商收官，正式进入结果等待期。新版国家基本医保药品目录与商保创新药目录预计11月正式公布，2027年1月1日起统一执行。此外，能源供给风险急剧升温，10年期美债收益率攀升至近三年高位，市场定价美联储下周加息25BP的概率已升至约70%。分析人士指出，近期创新药板块的调整，主要受到海外利率预期反复、油价上行推升通胀担忧、临床风险事件扰动及资金风格轮动等因素影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2242644610.SGD","LU1328277881.USD","LU0326950275.SGD","IE0008368742.USD","LU1188198961.HKD","LNGR","PEVC","LU1226287792.SGD","MCRO","KCAI","IE00BZ08YS42.EUR","LU1831875114.USD","IE0008369823.USD","LU0244354667.USD","01093","159992","BK4585","LU1008478684.HKD","LU2097828805.USD","LU2097828474.EUR","LU2097828557.USD","LU0501845795.SGD","09995","LU1960683339.HKD","LU2328871848.SGD","BK1161","06978","02157","BK1589","MEDX","WRTH","LU1226288170.HKD","01801","BK1191","IBBQ","LU0880133367.SGD","IE00B5MMRT66.SGD","BK1515","LU0067412154.USD","VXUS","KURE","LU1807302812.USD","IE00BZ08YT58.USD","LU0149534421.HKD","LU1226287875.USD","LU1969619763.USD","LU2488822045.USD","LU1813983027.USD","LU0455707207.USD","LU0072913022.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167697389","title":"乐普生物8月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1167697389","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167697389?lang=zh_cn&edition=full","pubTime":"2026-09-03 18:02","pubTimestamp":1788429720,"startTime":"0","endTime":"0","summary":"乐普生物科技股份有限公司于2026年9月3日披露了截至2026年8月31日的证券变动月报表。公告显示，报告期内，公司法定/注册股本维持为人民币1,804,439,838元，较上月无变化。截至8月末，乐普生物已发行股份总数为1,804,439,838股，其中无库存股，亦无新增发行、回购或注销行动。公司确认8月的公众持股量符合香港联合交易所有限公司相关规定的最低要求。该公告由联席公司秘书李昀軼女士于2026年9月3日签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773564","title":"港股异动 | 乐普生物(02157)午后涨超5% 上半年收入同比增长12.1% 即将跑通CMG901的BD全链条","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773564","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662773564?lang=zh_cn&edition=full","pubTime":"2026-08-27 13:54","pubTimestamp":1787810081,"startTime":"0","endTime":"0","summary":"消息面上，近日，乐普生物发布截至2026年6月30日止六个月业绩，收入5.22亿元，同比增长12.1%；公司拥有人应占利润2739.3万元，同比下降34.4%；每股基本盈利0.02元。国联民生证券发布研报称，乐普生物CMG901全球权益授权阿斯利康、MRG007大中华区外权益授权ArriVent，实现研发能力变现。在商业模式上，公司已成功构建并验证了国内商业化能力，同时即将跑通CMG901的BD全链条。这标志乐普生物能够通过国内商业化和海外授权双轮驱动，持续优化收入结构。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02157","KCAI","VXUS","BK4585","BK4588","BD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662566773","title":"港股异动 | 乐普生物(02157.HK)午后涨超5% 上半年收入同比增长12.1% 即将跑通CMG901的BD全链条","url":"https://stock-news.laohu8.com/highlight/detail?id=2662566773","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662566773?lang=zh_cn&edition=full","pubTime":"2026-08-27 13:54","pubTimestamp":1787810081,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162366260","title":"港股创新药概念股集体走强，中国生物制药涨超20%，石药集团涨超16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162366260","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162366260?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:59","pubTimestamp":1787191169,"startTime":"0","endTime":"0","summary":"8月20日，港股创新药概念股集体走强，$中国生物制药(01177)$涨超20%，$石药集团(01093)$涨超16%，$晶泰控股(02228)$、$金斯瑞生物科技(01548)$涨超12%，$乐普生物(02157)$、$康方生物(09926)$涨超11%，$荣昌生物(09995)$、$复星医药(02196)$涨超7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1521","IE0008368742.USD","IE00B543WZ88.USD","09926","159992","LU1226287875.USD","LU0880133367.SGD","IBBQ","BK1141","LU1961090484.USD","LU1152091754.HKD","LU1813983027.USD","LU2778985437.USD","LU0348767384.USD","IE00BZ08YT58.USD","BK1576","HK0000320223.HKD","BK1617","LU0315179316.USD","BK1161","BK1583","LU1226287529.USD","02228","LU0314109678.HKD","LU1226288253.USD","LU1807302812.USD","LU1226287792.SGD","IE00BPRC5H50.USD","LU1794554557.SGD","LU0417516902.SGD","BK1589","HK0000165453.HKD","IE00B5MMRT66.SGD","02157","LU0326950275.SGD","MEDX","LU2399975544.HKD","LU0348784397.USD","01093","01548","KCAI","LU2039709279.SGD","HK0000320264.USD","LU0067412154.USD","BK1593","LU1152091168.USD","LU0348827113.USD","01177","LU2476274720.SGD","VXUS","LU0348735423.USD","LU0540923850.HKD","LU0348783233.USD","LU0140636845.USD","LU0501845795.SGD","BK1191","IE00BZ08YS42.EUR","LU1951186391.HKD","SG9999004220.SGD","LNGR","02196","BK4588","LU1720050803.USD","LU2488822045.USD","LU0417516738.SGD","KURE","LU0348766576.USD","HK0000306701.USD","LU1960683339.HKD","LU1993786604.SGD","BK4585","BK1574","LU1226288170.HKD","BK1515","LU0072913022.USD","LU0417516571.SGD","LU1969619763.USD","LU2328871848.SGD","09995","HK0000306685.HKD","LU0634319403.HKD","LU1008478684.HKD","LU1328277881.USD","IE00BZ08YR35.GBP","IE00B031HY20.USD","LU0561508036.HKD","LU2476274308.USD","IE0008369823.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660247492","title":"乐普生物-B(2157.HK)中期业绩：营收5.22亿元同比增12%，中期继续盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2660247492","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660247492?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:01","pubTimestamp":1787187707,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660457094","title":"乐普生物(02157.HK)发布中期业绩，股东应占利润2739.3万元，同比下降34.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660457094","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660457094?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:43","pubTimestamp":1787129033,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109093580","title":"乐普生物（02157）2026年中期营收达5.22亿元  商业化销售翻倍助力扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1109093580","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109093580?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:42","pubTimestamp":1787128965,"startTime":"0","endTime":"0","summary":"8月19日，乐普生物科技股份有限公司披露截至2026年6月30日止六个月未经审计中期业绩。期内公司实现营收5.22亿元，同比增长12.1%，并连续两个报告期保持盈利，录得净利润0.25亿元。许可以及后续里程碑收入1.49亿元，主要源于CMG901及MRG007项目；受基数影响，较上年同期3.09亿元有所下降。CMG901一线联合治疗首名患者入组已触发4500万美元里程碑付款。财务表现方面，报告期内毛利4.75亿元；期末现金及现金等价物为6.85亿元。董事会宣布不派发中期股息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157871549","title":"乐普生物(02157)拟于2026年8月19日审议2026年中期业绩及派息事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1157871549","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157871549?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:05","pubTimestamp":1786100738,"startTime":"0","endTime":"0","summary":"乐普生物科技股份有限公司（02157）8月7日公告称，公司董事会会议定于2026年8月19日（星期三）举行。\n会议议程包括：  \n1. 审议及批准公司及其附属公司截至2026年6月30日止六个月的未经审计中期业绩及其发布；  \n2. 研究并考虑是否建议派发2026年中期股息（如有）；  \n3. 处理其他相关事项。\n公告显示，截至本公告日期，公司董事会由七名董事组成，其中执行董事两名，非执行董事两名，独立非执行董事三名。\n本次董事会结果及相关财务数据将在会议审议通过后另行公告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654071182","title":"港股异动 | 乐普生物(02157)涨近4% CMG901全球III期临床试验CLARITY-GASTRIC01取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2654071182","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654071182?lang=zh_cn&edition=full","pubTime":"2026-07-28 15:28","pubTimestamp":1785223688,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，乐普生物涨近4%，早盘曾涨逾12%。截至发稿，涨3.83%，报4.61港元，成交额9164.84万港元。消息面上，7月28日，乐普生物发布公告，有关集团与AstraZeneca AB就抗体偶联药物候选药物CMG901合作的最新情况。截至本公告日期，CLARITY-Gastric01全球III期临床试验公布的积极顶线结果显示，与研究者选择的治疗方案相比，sonesitatug vedotin在二线及后线(2L+) Claudin 18.2阳性晚期胃癌患者中展现出具有统计学显著性且极具临床意义的总生存期改善。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","IBBJ","BK4588","02157","KCAI","PSYK","BK1161","III","BMED","BK4134","VXUS","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654127078","title":"乐普生物：CMG901全球III期临床试验CLARITY-GASTRIC01达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2654127078","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654127078?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:32","pubTimestamp":1785213120,"startTime":"0","endTime":"0","summary":"【乐普生物：CMG901全球III期临床试验CLARITY-GASTRIC01达主要终点】乐普生物（02157.HK）发布自愿公告，公告基本信息：公司于2026年7月28日发布自愿性公告，披露其与阿斯利康合作开发的抗体偶联药物CMG901（sonesitatugvedotin，AZD0901）全球III期临床试验CLARITY-GASTRIC01取得积极顶线结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823312261.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823312261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["III","IBBQ","BMED","02157","IBBJ","PSYK","MDTX","BK1161","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654078997","title":"乐普生物(02157.HK)：CMG901(AZD0901)全球III期临床试验CLARITY-GASTRIC01取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2654078997","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654078997?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:31","pubTimestamp":1785213110,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136134951","title":"乐普生物（02157）与阿斯利康合作开发的CMG901全球III期CLARITY-GASTRIC01试验获积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1136134951","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136134951?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:30","pubTimestamp":1785213046,"startTime":"0","endTime":"0","summary":"2026年7月28日，乐普生物科技股份有限公司发布自愿性公告称，其与AstraZeneca AB合作开发的抗体偶联药物候选药物CMG901在全球III期临床试验CLARITY-GASTRIC01中取得积极顶线结果。试验显示，与研究者选择的治疗方案相比，CMG901在二线及后线（2L+）Claudin 18.2阳性晚期胃癌患者中，实现了具有统计学显著性且临床意义重大的总生存期改善。除CLARITY-GASTRIC01外，AstraZeneca正开展多项针对胃癌、胰腺癌及胆道癌等适应症的CMG901临床研究，包括III期CLARITY-Gastric 02、II期GEMINI-PeriOp GC及II期CLARITY-PanTumour01等。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lepubiopharma.com","stockEarnings":[{"period":"1week","weight":0.0276},{"period":"1month","weight":-0.1011},{"period":"3month","weight":-0.0907},{"period":"6month","weight":-0.344},{"period":"1year","weight":-0.5044},{"period":"ytd","weight":-0.2133}],"compareEarnings":[{"period":"1week","weight":-0.0244},{"period":"1month","weight":-0.0628},{"period":"3month","weight":0.0231},{"period":"6month","weight":-0.0716},{"period":"1year","weight":-0.1142},{"period":"ytd","weight":-0.062}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"乐普生物科技股份有限公司是一家主要从事医药产品销售及新药研发的公司。该公司聚焦于肿瘤治疗领域，尤其是靶向治疗及免疫治疗。该公司致力于通过抗体药物偶联物（ADC）技术开发平台开发创新型ADC。该公司的临床阶段候选药物涵盖靶向疗法药物和一种免疫治疗药物，具体包括MRG003、MRG002、CMG901、MRG004A、CG0070、MRG006A、MRG007、CTM012等。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.070458},{"month":2,"riseRate":0.5,"avgChangeRate":0.087235},{"month":3,"riseRate":0.4,"avgChangeRate":-0.009016},{"month":4,"riseRate":0.8,"avgChangeRate":0.177486},{"month":5,"riseRate":0.4,"avgChangeRate":-0.041488},{"month":6,"riseRate":0.4,"avgChangeRate":-0.053819},{"month":7,"riseRate":0.6,"avgChangeRate":0.074049},{"month":8,"riseRate":0.6,"avgChangeRate":0.005043},{"month":9,"riseRate":0.4,"avgChangeRate":0.05935},{"month":10,"riseRate":0.2,"avgChangeRate":-0.128644},{"month":11,"riseRate":0.25,"avgChangeRate":0.007333},{"month":12,"riseRate":0.25,"avgChangeRate":-0.05091}],"exchange":"SEHK","name":"乐普生物","nameEN":"LEPU BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"乐普生物(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供乐普生物(02157)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"乐普生物,02157,乐普生物股票,乐普生物股票老虎,乐普生物股票老虎国际,乐普生物行情,乐普生物股票行情,乐普生物股价,乐普生物股市,乐普生物股票价格,乐普生物股票交易,乐普生物股票购买,乐普生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"乐普生物(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供乐普生物(02157)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}